Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2024 Feb 24

PMID 38397436

Authors

Umberto Attanasio

Elena Di Sarro

Lucia Tricarico

Daniela Di Lisi

Giuseppe Armentaro

Sofia Miceli

Francesco Fioretti

Martino Deidda

Michele Correale

Giuseppina Novo

Angela Sciacqua

Savina Nodari

Christian Cadeddu

Carlo Gabriele Tocchetti

Alberto Palazzuoli

Valentina Mercurio

Affiliations

Soon will be listed here.

Abstract

Serum biomarkers represent a reproducible, sensitive, minimally invasive and inexpensive method to explore possible adverse cardiovascular effects of antineoplastic treatments. They are useful tools in risk stratification, the early detection of cardiotoxicity and the follow-up and prognostic assessment of cancer patients. In this literature review, we aim at describing the current state of knowledge on the meaning and the usefulness of cardiovascular biomarkers in patients with cancer; analyzing the intricate relationship between cancer and cardiovascular disease (especially HF) and how this affects cardiovascular and tumor biomarkers; exploring the role of cardiovascular biomarkers in the risk stratification and in the identification of chemotherapy-induced cardiotoxicity; and providing a summary of the novel potential biomarkers in this clinical setting.

Citing Articles

Cancer and myocardial injury in patients with suspected acute coronary syndrome.

Sabate-Tormos M, Bardaji A, Peiro O, Carrasquer A, Cediel G, Ferreiro J Cardiooncology. 2025; 11(1):21.

PMID: 39987454 PMC: 11846249. DOI: 10.1186/s40959-025-00320-x.

Facilities in Molecular Biomarkers in Cardiology.

Scicchitano P, Cameli M Biomolecules. 2024; 14(8).

PMID: 39199412 PMC: 11352323. DOI: 10.3390/biom14081025.

References

Meijers W, Maglione M, Bakker S, Oberhuber R, Kieneker L, de Jong S . Heart Failure Stimulates Tumor Growth by Circulating Factors. Circulation. 2018; 138(7):678-691. DOI: 10.1161/CIRCULATIONAHA.117.030816. View

Tini G, Cuomo A, Battistoni A, Sarocchi M, Mercurio V, Ameri P . Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice. Int J Cardiol. 2021; 349:134-137. DOI: 10.1016/j.ijcard.2021.11.059. View

Mahmood S, Fradley M, Cohen J, Nohria A, Reynolds K, Heinzerling L . Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018; 71(16):1755-1764. PMC: 6196725. DOI: 10.1016/j.jacc.2018.02.037. View

Armenian S, Hudson M, Mulder R, Chen M, Constine L, Dwyer M . Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015; 16(3):e123-36. PMC: 4485458. DOI: 10.1016/S1470-2045(14)70409-7. View

Danese E, Montagnana M, Giudici S, Aloe R, Franchi M, Guidi G . Highly-sensitive troponin I is increased in patients with gynecological cancers. Clin Biochem. 2013; 46(12):1135-1138. DOI: 10.1016/j.clinbiochem.2013.04.029. View

Ky B, Putt M, Sawaya H, French B, Januzzi Jr J, Sebag I . Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2013; 63(8):809-16. PMC: 4286181. DOI: 10.1016/j.jacc.2013.10.061. View

Jensen B, Parry T, Huang W, Beak J, Ilaiwy A, Bain J . Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis. Br J Pharmacol. 2017; 174(24):4797-4811. PMC: 5727336. DOI: 10.1111/bph.14062. View

Pudil R, Mueller C, Celutkiene J, Henriksen P, Lenihan D, Dent S . Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020; 22(11):1966-1983. DOI: 10.1002/ejhf.2017. View

Vasan R . Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006; 113(19):2335-62. DOI: 10.1161/CIRCULATIONAHA.104.482570. View

10.

von Haehling S, Doehner W, Anker S . Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res. 2006; 73(2):298-309. DOI: 10.1016/j.cardiores.2006.08.018. View

11.

Putt M, Hahn V, Januzzi J, Sawaya H, Sebag I, Plana J . Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab. Clin Chem. 2015; 61(9):1164-72. PMC: 4667170. DOI: 10.1373/clinchem.2015.241232. View

12.

Tan G, Lou Z, Liao W, Zhu Z, Dong X, Zhang W . Potential biomarkers in mouse myocardium of doxorubicin-induced cardiomyopathy: a metabonomic method and its application. PLoS One. 2011; 6(11):e27683. PMC: 3218026. DOI: 10.1371/journal.pone.0027683. View

13.

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

14.

Mayer Jr O, Simon J, Plaskova M, Cifkova R, Trefil L . N-terminal pro B-type natriuretic peptide as prognostic marker for mortality in coronary patients without clinically manifest heart failure. Eur J Epidemiol. 2009; 24(7):363-8. DOI: 10.1007/s10654-009-9339-6. View

15.

Piek A, Meijers W, Schroten N, Gansevoort R, de Boer R, Sillje H . HE4 Serum Levels Are Associated with Heart Failure Severity in Patients With Chronic Heart Failure. J Card Fail. 2016; 23(1):12-19. DOI: 10.1016/j.cardfail.2016.05.002. View

16.

Skala M, Hanouskova B, Skalova L, Matouskova P . MicroRNAs in the diagnosis and prevention of drug-induced cardiotoxicity. Arch Toxicol. 2018; 93(1):1-9. DOI: 10.1007/s00204-018-2356-z. View

17.

Friedman R, Farh K, Burge C, Bartel D . Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008; 19(1):92-105. PMC: 2612969. DOI: 10.1101/gr.082701.108. View

18.

Lestuzzi C, Stolfo D, De Paoli A, Banzato A, Buonadonna A, Bidoli E . Cardiotoxicity from Capecitabine Chemotherapy: Prospective Study of Incidence at Rest and During Physical Exercise. Oncologist. 2022; 27(2):e158-e167. PMC: 8895550. DOI: 10.1093/oncolo/oyab035. View

19.

Li K, Gong M, Li G, Baranchuk A, Liu T, Wong M . Cancer antigen-125 and outcomes in acute heart failure: a systematic review and meta-analysis. Heart Asia. 2018; 10(2):e011044. PMC: 6204439. DOI: 10.1136/heartasia-2018-011044. View

20.

Lyon A, Lopez-Fernandez T, Couch L, Asteggiano R, Aznar M, Bergler-Klein J . 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022; 23(10):e333-e465. DOI: 10.1093/ehjci/jeac106. View